

Freedom of Information Request: Our Reference CTMUHB_451_23

You asked:

I have a freedom of information request.

A. We are seeking to understand the funding and delivery of Botox and anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality, Vyepti, Vydura & Aquipta) for migraine. Could you please answer the following:

- **Does the trust commission/fund Botox treatment for migraine (Y/N)?**

Yes.

- **Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)?**

Yes.

- **Does the trust actively provide Botox/anti-CGRP treatments for migraine as opposed to sending patients to another trust (Y/N)? In case the trust does not provide these treatments, please provide the name of the trust to which you refer migraine patients for these treatments?**

Yes.

- **In case the trust actively provides Botox/anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.**

Funded by the Health Board.

B. How many patients have been treated with the following drugs in the past 4 months:

- **Atogepant (Aiqupta) – any disease**
- **Erenumab (Aimovig) - any disease**
- **Eptinezumab (Vyepti) – any disease**
- **Fremanezumab (Ajovy) - any disease**
- **Galcanzumab (Emgality) - any disease**
- **Rimegepant (Vydura) – any disease**
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY**

Please see provided below tables populated with the data requested. The period the data covers is June 23 to September 23.

Where the patient figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Medicine	Number of Patients
Atogepant (Aquipta)	0
Erenumab (Aimovig)	6
Fremanezumab (Ajovy)	45
Glacanezumab (Emgality)	6
Rimegepant (Vydura)	**

Please note that we are unable to provide the number of patients or define as migraine only treated with Botulinum Toxin as this detail is not captured on our Medicine Management system. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

However, to assist you with your request we have provided data on the number of vials issued for any condition.

Medicine	Strength	Number of Vials
Botulinum Toxin - Botox	50mg	43
Botulinum Toxin - Botox	100mg	74
Botulinum Toxin - Botox	200mg	97
Botulinum Toxin - Dysport	300mg	2
Botulinum Toxin - Dysport	500mg	2
Botulinum Toxin - Xeomin	50 units	33
Botulinum Toxin - Xeomin	100 units	7